Schrodinger, Inc. (NASDAQ:SDGR) Stock Has Average Price Target of $20.50

Schrodinger, Inc. (NASDAQ:SDGR) has earned an average rating of “Hold” from the seven brokerages that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $20.50.

A number of research firms have recently commented on SDGR. UBS Group started coverage on shares of Schrodinger in a research report on Friday, August 14th. They set a “neutral” rating and a $19.00 price target for the company. Weiss Ratings upgraded Schrodinger from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. Finally, Wall Street Zen raised Schrodinger from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 8th.

Schrodinger Trading Down 2.0%

SDGR stock opened at $28.85 on Friday. The firm has a 50 day moving average of $19.88 and a 200-day moving average of $15.78. The firm has a market capitalization of $2.13 billion, a P/E ratio of -38.99 and a beta of 1.69. Schrodinger has a 12 month low of $10.94 and a 12 month high of $31.59.

Schrodinger (NASDAQ:SDGR) last posted its earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.49. Schrodinger had a negative net margin of 20.98% and a negative return on equity of 16.37%. The business had revenue of $58.89 million for the quarter, compared to analyst estimates of $47.19 million. During the same quarter in the prior year, the firm posted ($0.65) EPS. Schrodinger’s revenue was up 7.5% on a year-over-year basis. Sell-side analysts predict that Schrodinger will post -1.5 EPS for the current year.

Insiders Place Their Bets

In other Schrodinger news, insider Karen Akinsanya sold 31,599 shares of the firm’s stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $29.37, for a total value of $928,062.63. Following the sale, the insider owned 69,956 shares of the company’s stock, valued at $2,054,607.72. This trade represents a 31.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.10% of the stock is owned by corporate insiders.

Institutional Trading of Schrodinger

Institutional investors and hedge funds have recently made changes to their positions in the stock. Handelsbanken Fonder AB grew its position in Schrodinger by 6.3% in the fourth quarter. Handelsbanken Fonder AB now owns 15,200 shares of the company’s stock worth $272,000 after acquiring an additional 900 shares in the last quarter. Kestra Advisory Services LLC raised its position in Schrodinger by 2.0% during the first quarter. Kestra Advisory Services LLC now owns 51,429 shares of the company’s stock valued at $584,000 after purchasing an additional 1,002 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Schrodinger by 722.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,374 shares of the company’s stock worth $25,000 after purchasing an additional 1,207 shares during the last quarter. Hantz Financial Services Inc. lifted its stake in Schrodinger by 5,025.8% during the fourth quarter. Hantz Financial Services Inc. now owns 1,589 shares of the company’s stock worth $28,000 after purchasing an additional 1,558 shares during the last quarter. Finally, Stephens Inc. AR boosted its holdings in shares of Schrodinger by 15.8% in the 4th quarter. Stephens Inc. AR now owns 12,618 shares of the company’s stock worth $226,000 after purchasing an additional 1,724 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

About Schrodinger

Schrödinger, Inc develops computational software designed to accelerate drug discovery and materials science research. Its platform uses physics-based modeling, machine learning and related computational methods to help scientists analyze molecular structures, predict interactions and identify potential compounds for further development.

The company’s software products support a range of research activities, including molecular modeling, virtual screening, structure-based drug design, free-energy calculations and collaborative data management.